𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines

✍ Scribed by Charlotte Wilson; Jinshu Yang; Jon C. Strefford; Brenda Summersgill; Bryan D. Young; Janet Shipley; Tim Oliver; Yong-Jie Lu


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
140 KB
Volume
43
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Testicular germ‐cell tumors (TGCTs) show exquisite sensitivity to cisplatin‐based chemotherapy, and therefore this is considered a good model system for studying the mechanism of chemotherapy resistance. Although the genetic alterations related to TGCT have been well studied, little is known about the genetic basis of chemotherapy resistance, which occurs in a small proportion of TGCTs. In this study, we investigated genomic and expression differences between three cisplatin‐sensitive and their paired cisplatin‐resistant lines using combined whole‐genome screen approaches. Comparative genomic hybridization (CGH) analysis on chromosomes revealed genetic differences between the resistant and parent cell lines in each pair, but did not show any consistent chromosome changes in all three lines. Microarray CGH analysis generated some additional information of DNA copy number gains and losses including some important oncogenes, tumor‐suppressor genes, and drug‐resistance‐related genes. However, no consistent genomic region changes were found in the three cell lines. Interestingly, when comparative expressed sequence hybridization, a technique for gene expression profiling along chromosomes, was applied, we discovered a consistently overexpressed chromosomal region in all three resistant lines compared with their parent lines. The minimum overlapping chromosomal region is at 16q22–23. Further definition of genes in this chromosomal region will aid our understanding of the mechanism of cisplatin resistance and may offer novel therapeutic targets. © 2005 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Identification of genomic changes associ
✍ Elodie E. Noel; Jackie Perry; Tracy Chaplin; Xueying Mao; Jean-Baptiste Cazier; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 321 KB 👁 1 views

## Abstract Since the introduction of cisplatin into the clinic, the treatment of patients with a variety of solid tumors including testicular germ cell tumors, ovarian and lung cancers, has dramatically improved. One of the main causes for therapeutic failure in these malignancies is the developme

Acquired cisplatin resistance in the hea
✍ Eva M. Gosepath; Niels Eckstein; Alexandra Hamacher; Kati Servan; Georg von Jonq 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 301 KB 👁 1 views

## Abstract Head and neck cancers are treated by a combination of surgery, radiotherapy and/or chemotherapy. The clinical success of cisplatin‐based chemotherapy, mostly in combination with 5‐FU or a taxane, is however limited by multifactorial intrinsic or acquired resistance. So far, known genes

Establishment of a novel human B-cell li
✍ M. Nagai; M. Fujita; M. Ohmori; S. Matsubara; M. Taniwaki; S. Horiike; T. Tasaka 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 1 views

The novel human pre-B cell line OZ was established from a patient with an aggressive form of non-Hodgkin's lymphoma. Karyotypic analysis of both the primary tumour and OZ cells revealed several marker chromosomes, including the t(14;18)(q32;q21) translocation, which involves the Bcl-2 gene, and alte